Loading data
CDTNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development expense | 5.05 m USD | 3.38 m USD | 90 k USD | 37 k USD |
| Operating profit | -36.8 m USD | -15.42 m USD | -5.3 m USD | -3.16 m USD |
| Interest expense | 200 k USD | 32 k USD | — | 100 k USD |
| Profit before tax | -39.22 m USD | -17.8 m USD | -536 k USD | 773.5 k USD |
| Income tax expense | — | — | — | 374.86 k USD |
| Net income (reported basis) | -39.22 m USD | -17.8 m USD | -535 k USD | -4.9 m USD |
| Net income attributable to common shareholders | -39.22 m USD | -17.8 m USD | -535 k USD | -4.89 m USD |
| Basic earnings per share | -11,779.12 USD/share | -612,360.21 USD/share | -0.79 USD/share | -0.13 USD/share |
| Diluted earnings per share | -11,779.12 USD/share | -612,360.21 USD/share | -8.92 USD/share | -0.13 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.